OSTEOPOROSIS

Abstract

Osteoporosis represents the most common form of metabolic bone disease. Its epidemiology, pathogenesis, clinical manifestations, radiographic and laboratory features, bone density measurements, and treatment are discussed.
Key Words : Postmenopausal osteoporosis, Bone mineral density, HRT, Bisphosphonates

References

1. Melton LJ, Eddy DM, Johnston CC Jr. Screening for osteoporosis. Ann Int Med 1990; 112:516-528.
2. Consensus Development Conference. Consensus development conference:diagnosis, prophylaxis, and treatment of osteoporosis. Am J Med 1993;94:646-650.
3. Kanis JA, Melton LJ, Christiansen C.et a!. The diagnosis of osteoporosis. J Bone Miner Res 1994:9:! 137-1 146.
4. Browner WS, Pressman AR, Mevitt MC, et al. Mortality following fractures in older women. The study of osteoporotic fractures. Arch Intern Med 1996:156:1521-1525.
5. Looker AC, Orwoll ES, Johnston CC, et al. Prevalence of low bone density in older US adults from nLIAMES III. J Bone Miner Res 1997,12:1761- 1769.
6. Melton LJ, Chrischilles EA, Cooper C, et al. Dow many women have osteoporosis? J Bone Miner Res 1992:7:1005-1007.
7. Mordin BEC, Meed AG, Bridges A, Dorowitz M. Relative contributions of years since menopause, age, and weight to vertebral density in postmenopausal women. J Clin Endocrinol Metab 1992;74:20-23.
8. Riis B, Thomsen K, Christiasen C. Does calcium supplementation prevent postmenopausal bone loss? A double-blind, controlled clinical study. M Engl J Med 198 7:316:173-177.

9. Chetkowski RJ, Meldrum DR, Steingold KA, et at. Biologic effects of transdermal estradiol. M Engl J Med 1986:314:1615-1620.
10. Parisien M, Silverberg SJ, Shane E, et al. The histomorphometry of bone in primary hyperparathyroidism:Preservation of cancellous bone structure. J Clin Endocrinol Metab 1990:70:930-937.
11. Mosekilde L, Melsen F. A tetracycline-based histomorphometric evaluation of bone resorption and bone turnover in hyperthyroidism and hyperparathyroidism. Acta Med Scand 1978:204:97-101.
12. Rigotti MA, Mussbaum SR, Derzog DB, Meer RM. Osteoporosis in women with anorexia nervosa. M Engl J Med 1984;311:1601-1606.
13. Klibanski A, Biller BM, Schoenfeld DA, et al. The effects of estrogen administration on trabecular bone loss in young women with anorexia nervosa. J Clin Endocrinol Metab 1995:80:898-904.
14. Counts DR, Gwirtsman 11, Carlsson LM, et al. The effects of anorexia nervosa and refeeding on growth hormone-binding protein, the insulin-like growth factors (IGFs), and the IGF-binding proteins. J Clin Endocrinol Metab 1992;75:762-767.
15. Grlnspoon Sli, Baum DB, Peterson S, Klibanski /t. Effects of rhIGF-l administration on bone turnover during short-term fasting. J Clin Invest 1995:96:900-906.
16. Rosen DM. Primary biliary cirrhosis and bone disease. Depatology 1995;21:253-259.
17. Riggs BL, Melton LJ. Involutional osteoporosis. M Engl J Med 1986:314:1676-1686.
18. Chapuy MC, Arlott ME.Duboeuf F.et al. Vitamin D3 and calcium to prevent hip fractures in elderly women. M Engl J Med 1992;327:1637-1642.
19. Ettinger B, Pressman A, Sklarin P, et al. Associations between low levels of estradiol, bone density, and fractures among elderly women: The Study of Osteoporotic Fractures.J Clin Endocrinol Metab 1998:83:2239-2243.
20. Cummings SR, Browner WS, Bauer D, et al. For the Study of Osteoporotic Fractures Research Group. Endogenous hormones and the risk of hip and vertebral fractures among older women. M Engl J Med 1998:339:733-738.
21. Prince RL, Smith M, Dick IM, et al. Prevention of postmenopausal osteoporosis: /I comparative study of exercise,calcium supplementation, and hormone-replacement therapy. M Engl J Med 1991:325:1 189-1 195.
22. Gênant DK, Cann CE, Ettinger B, Gordan GS. Quantitative computed tomography of vertebral spongiosa: A sensitive method for detecting early bone loss after oophorectomy. Ann Intern Med 1982:97:699-705.
23. Gallagher JC, Kable WT, Goldgar D. Effect of progestin therapy on cortical and trabecular bone: Comparison with estrogen. Am J Med 1991:90:171- 176.
24. Kelepouris M, Darper KD, Gannon F, et al. Severe osteoporosis in men. Ann Intern Med 1995:123:452-460.
25. Behre DM, Kliesch S, Leifke E, et al. Long-term effect of testosterone therapy on bone mineral density in hypogonadal men. J Clin Endocrinol Metab 1997;82:2386-2390.
26. Soule SG, Conway G, Prelevic GM, et al. Osteopenia as a feature of the androgen insensitivity syndrome. Clin Endocnnol 1995;43:671-674.
27. Slemenda CW, Longcope C, Zhou L, et al. Sex steroids and bone mass in older mass. Positive associations with serum estrogens and negative associations with androgens. J Clin Invest 1997,100:1755-1759.
28. Smith EP, Boyd J, Frank GR, et al. Estrogen resistance caused by a mutation in the estrogen- receptor gene in a man. hi Engl J Med 1994;331:1056-1062.
29. Carani C, Qin R, Simoni M, et al. Effect of testosterone and estradiol in a man with aromatase deficiency, hi Engl J Med 1997;337:91-95.
30. Slemenda C, Longcope C, Peacock M, et al. Sex steroids, bone mass and bone loss. J Clin Invest 1996;97:14-21.
31. Riggs BL. Vitamin D-receptor genotypes and bone density, hi Engl J Med 1997;337:125-126.
32. Uitterlinden AG, Burger ft, Huang Q, et al. Relation of alleles of the collagen type la I gene to bone density and the risk of osteoporotic fractures in postmenopausal women. hi Engl J Med 1998;338:1016-1021.
33. Hopper JL, Seeman E. The bone density of female twins discordant for tobacco use. hl Engl J Med 1994;330:387-392.
34. Bjarnason 1, Macpherson A, Mackintosh C, et al. Reduced bone density in patients with inflammatory bowel disease. Gut 1997;40:228-233.
35. Liu B, Anderson G, Mittman hi, et at. Use of selective serotonin-reuptake inhibitors or tricyclic antidepressants and risk of hip fractures in elderly people. Lancet 1998;351:1303-1307.
36. Ensrud RE, Lipschutz MP, Cauley JA. Body size and hip fracture risk in older women: A prospective study. Am J Med 1997,103:274-280.
37. Rleerekoper M, Avioli LV. Evaluation and treatment of postmenopausal osteoporosis, ln: Favus MJ, Ed. Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism 2nd ed. Lippincott- Raven, Philadelphia, 1993:223-229.
38. Jackson JA. Osteoporosis in men. In: Favus MJ, Ed. Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism. 2nd ed. Lippincott-Raven, Philadelphia, 1993:255-258.
39. Gênant HR, Engelke R, Fuerst T, et al. hloninvasive assesment of bone mineral and structure: State of the art. J Bone Miner Res 1996; 1 1.707-712.
40. Dawson-Hughes B, Dallai GE, Rrall EA, et al. Controlled trial of the effect of calcium supplementation on bone density in postmenopausal women, hi Engl J Med 1990; 323:878-883.
41. Recker RR, Davies RM, Dowd RM, Heany RP. The effect of low-dose continuous estrogen and progesterone therapy with calcium and vitamin D on bone in elderly women. Ann Int Med 1999; 130:897-904.
42. Rhouidhunkit W, Shoback DM. Clinical effects of raloxifene hydrochloride in women. Ann Int Med 1999;130:431-439.
43. Avioli LV. Heterogeneity of osteoporotic syndromes and the response to calcitonin therapy. Calcific Tissue Int 1991;49 (Suppl 2): SI6-19.
44. Tilyard MW, Spears GFS, Thompson J, Dovey S. Treatment of postmenopausal osteoporosis with calcitriol or calcium, hi Engl J Med 1992; 326:357- 361.
45. Wimalawansa SJ. Combined therapy with estrogen and etidronate has an additive effect on bone mineral density in the hip and vertebrae: Four year randomized study. Am J Med 1995:99:36-42.
46. Rarpf DB, Shapiro DR, Seeman, et al. Prevention of nonvertebral fractures by alendronate. A metaanalysis. JAMA 1997; 277:115-121.